Gene: UBLCP1
Official Full Name: ubiquitin like domain containing CTD phosphatase 1provided by HGNC
Gene Summary: Enables proteasome regulatory particle binding activity and protein serine/threonine phosphatase activity. Involved in negative regulation of ATP-dependent activity and regulation of proteasome assembly. Located in nucleolus and nucleoplasm. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO26434 | UBLCP1 Knockout cell line (HeLa) | Human | UBLCP1 | 1:3~1:6 | Negative | Online Inquiry |
KO26435 | UBLCP1 Knockout cell line (HCT 116) | Human | UBLCP1 | 1:2~1:4 | Negative | Online Inquiry |
KO26436 | UBLCP1 Knockout cell line (HEK293) | Human | UBLCP1 | 1:3~1:6 | Negative | Online Inquiry |
KO26437 | UBLCP1 Knockout cell line (A549) | Human | UBLCP1 | 1:3~1:4 | Negative | Online Inquiry |
UBLCP1 Gene Knockout Cell Lines are specifically engineered cellular models that facilitate the comprehensive study of the UBLCP1 gene's functions and its implications in various biological processes. These lines are created using CRISPR-Cas9 technology, resulting in precise deletions or disruptions in the UBLCP1 gene sequence. This genetic modification enables researchers to investigate the gene's role in processes such as protein degradation, cell cycle regulation, and stress response mechanisms, thereby providing insights into cellular homeostasis and pathophysiology.
Functionally, UBLCP1 Gene Knockout Cell Lines allow scientists to assess the impact of the UBLCP1 gene loss on cellular phenotypes, including proliferation, apoptosis, and metabolic activity. By comparing these knockout models to wild-type counterparts, researchers can elucidate the downstream effects of UBLCP1 gene disruption, which is crucial for understanding various diseases, including cancer, metabolic disorders, and neurodegenerative conditions.
The scientific relevance of UBLCP1 Gene Knockout Cell Lines extends to both basic and applied research. In academic settings, they serve as vital tools for elucidating gene function, while in clinical research, they hold promise for drug discovery and the development of targeted therapies. Moreover, these cell lines can be utilized to screen compounds that may restore normal function or compensate for UBLCP1 loss.
Distinct from alternative models, our UBLCP1 Gene Knockout Cell Lines are rigorously validated for gene editing efficiency and off-target effects, ensuring high fidelity in experimental outcomes. This feature is particularly advantageous for researchers seeking reliable and reproducible results.
By providing a robust platform for genetic analysis, our UBLCP1 Gene Knockout Cell Lines empower researchers and clinicians to advance their understanding of gene function in health and disease. Our company prides itself on its state-of-the-art gene editing capabilities and commitment to quality, making us a trusted partner in the life sciences field.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.